Compact Device Developed for Sorting Cells and Biomolecules
|
By LabMedica International staff writers Posted on 20 Nov 2017 |

Image: The developed sorting chip for analyzing and isolating cells in a blood sample (Photo courtesy of the Fraunhofer Institute of Laser Technology).
Biomolecules and cells circulating in the blood carry diagnostic information, the analysis of which makes highly effective, individualized therapies possible.
A microchip-based diagnostic device has been developed that analyzes and sorts clinically relevant biomolecules and cells in a blood test with light. As a result, physicians can make early diagnoses, for example, of tumor and cardiovascular diseases and initiate patient-specific therapies with great efficacy.
Biomedical engineers at the Fraunhofer Institute of Laser Technology (Aachen, Germany) have developed the “AnaLighter” which is a compact diagnostic device for sorting cells and biomolecules. Its technological core is based on an optically switchable microfluidic chip whose optical sensors and switches are connected to the chip via optical fibers. The “Microchip Based Fluorescence Activated Cell Sorter” (μFACS) functions in the following way: The biomolecules and cells to be analyzed by fluorescence are guided through a microfluidic channel and focused hydrodynamically on a cross-section of 10 μm at the site of the optical measurement. Laser light from an optical fiber stimulates the analyte in the microfluidic channel to fluoresce.
Then, micro-optics focus the laser light emerging from the fiber into the microfluidic channel, collect the fluorescent light generated there and guide it through optical fibers to the photodetector. This fiber-optic design allows a significant reduction in the installation space and makes the μFACS more rugged compared to the prior state-of-the-art. The “AnaLighter technology” is, therefore, ideally suited for automated diagnostic applications in 24/7 operation.
The spectrally separated detection channels of the “AnaLighter” can simultaneously detect different marker molecules in the blood. In such multiplex diagnostics, these marker molecules from a blood sample are specifically bound by a mixture of microparticles, each particle species binding exactly one molecule species to be detected. The μFACS technology can also process water-in-oil emulsions in addition to aqueous solutions in contrast to conventional FACS systems.
The detection of bound marker molecules is encoded by a characteristic fluorescence label and its signal measured by one of the 16 detection channels. Such multiplex diagnosis can detect up to 16 different disease markers with only one measurement run. In annual routine checks, a general practitioner can detect a large number of possible diseases early in the course of a single blood test in order to prevent widespread diseases, such as cardiovascular disease. The sorting function also makes it possible to separate out the appropriate candidates from the others during screening, in order to dispose of the relevant gene sequences in for example genetically modified variants. The device was demonstrated at the COMPAMED 2017 held November 13-16, 2017, in Düsseldorf, Germany.
Related Links:
Fraunhofer Institute of Laser Technology
A microchip-based diagnostic device has been developed that analyzes and sorts clinically relevant biomolecules and cells in a blood test with light. As a result, physicians can make early diagnoses, for example, of tumor and cardiovascular diseases and initiate patient-specific therapies with great efficacy.
Biomedical engineers at the Fraunhofer Institute of Laser Technology (Aachen, Germany) have developed the “AnaLighter” which is a compact diagnostic device for sorting cells and biomolecules. Its technological core is based on an optically switchable microfluidic chip whose optical sensors and switches are connected to the chip via optical fibers. The “Microchip Based Fluorescence Activated Cell Sorter” (μFACS) functions in the following way: The biomolecules and cells to be analyzed by fluorescence are guided through a microfluidic channel and focused hydrodynamically on a cross-section of 10 μm at the site of the optical measurement. Laser light from an optical fiber stimulates the analyte in the microfluidic channel to fluoresce.
Then, micro-optics focus the laser light emerging from the fiber into the microfluidic channel, collect the fluorescent light generated there and guide it through optical fibers to the photodetector. This fiber-optic design allows a significant reduction in the installation space and makes the μFACS more rugged compared to the prior state-of-the-art. The “AnaLighter technology” is, therefore, ideally suited for automated diagnostic applications in 24/7 operation.
The spectrally separated detection channels of the “AnaLighter” can simultaneously detect different marker molecules in the blood. In such multiplex diagnostics, these marker molecules from a blood sample are specifically bound by a mixture of microparticles, each particle species binding exactly one molecule species to be detected. The μFACS technology can also process water-in-oil emulsions in addition to aqueous solutions in contrast to conventional FACS systems.
The detection of bound marker molecules is encoded by a characteristic fluorescence label and its signal measured by one of the 16 detection channels. Such multiplex diagnosis can detect up to 16 different disease markers with only one measurement run. In annual routine checks, a general practitioner can detect a large number of possible diseases early in the course of a single blood test in order to prevent widespread diseases, such as cardiovascular disease. The sorting function also makes it possible to separate out the appropriate candidates from the others during screening, in order to dispose of the relevant gene sequences in for example genetically modified variants. The device was demonstrated at the COMPAMED 2017 held November 13-16, 2017, in Düsseldorf, Germany.
Related Links:
Fraunhofer Institute of Laser Technology
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







